Open AccessTRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies
Author(s) -
Bruno Christian Koehler,
Toni Urbanik,
Binje Vick,
Regina Boger,
Steffen Heeger,
Peter R. Galle,
Marcus Schuchmann,
Henning SchulzeBergkamen
Publication year - 2009
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.15.5924
Subject(s) - apoptosis , sorafenib , cancer research , kinase , flow cytometry , pi3k/akt/mtor pathway , biology , microbiology and biotechnology , chemistry , hepatocellular carcinoma , biochemistry
To analyze the effect of chemotherapeutic drugs and specific kinase inhibitors, in combination with the death receptor ligand tumor necrosis factor-related apoptosis inducing ligand (TRAIL), on overcoming TRAIL resistance in hepatocellular carcinoma (HCC) and to study the efficacy of agonistic TRAIL antibodies, as well as the commitment of antiapoptotic BCL-2 proteins, in TRAIL-induced apoptosis.